#Germany #Veeva Systems #Boehringer Ingelheim #Ingelheim #One Medicine

Boehringer Ingelheim and Veeva: Pioneering a New Era in Drug Development

In an ambitious move to transform the landscape of drug development, Boehringer Ingelheim has partnered with Veeva Systems to launch the groundbreaking One Medicine Platform. Announced on March 11, 2025, this union marks a significant evolution in how biopharmaceutical companies can streamline the development of treatments aimed at currently incurable diseases.

The Genesis of One Medicine Platform

The journey began back in March 2022 when the two companies first hinted at their collaboration. With the integration of Veeva's Development Cloud, Boehringer aims to consolidate its data and processes from various divisions including clinical, regulatory, and quality functions. This will not only enhance operational efficiency but also streamline the process of bringing new medicines to market.

How It Works

The One Medicine Platform is designed to connect data across diverse functions. By breaking down silos within the organization, it enables a more cohesive approach to drug development. Oliver Fink, head of learning, process and digitalization at Boehringer Ingelheim, elaborated on the vision behind this initiative, stating, "Together with Veeva, we aim to accelerate the delivery of innovative, life-transforming treatments to patients across the globe."

Veeva's Development Cloud provides a robust technological framework for this platform, empowering teams at Boehringer to design and conduct clinical trials that are not only faster but also more compliant with industry regulations. Rik van Mol, Senior Vice President at Veeva, emphasized that by uniting clinical, regulatory, and quality data, they can significantly expedite drug development processes and regulatory approvals.

The Broader Impact

The launch of the One Medicine Platform is expected to have far-reaching consequences in the biopharmaceutical sector. With drug development timelines often spanning a decade or longer, the ability to use advanced technology to bridge gaps in data and collaboration could ultimately lead to faster and more effective treatment options for patients currently battling diseases with limited or no effective treatments.

Boehringer Ingelheim, a prominent player in both human and animal health, has long been committed to addressing areas of high unmet medical need. As one of the top investors in research and development, the company actively seeks to innovate therapies that could change lives. The commitment to sustainability is woven into their operational ethos, which has been a core tenet since its establishment in 1885.

Meanwhile, Veeva Systems has established itself as a leader in cloud software dedicated to the life sciences sector. With a customer base of over a thousand organizations—ranging from large biopharmaceutical companies to emerging startups—Veeva has emphasized its commitment to innovation and customer success, serving the diverse needs within this highly specialized industry.

Looking Ahead

As the world eagerly awaits the outcomes of this partnership, it is clear that the One Medicine Platform is poised to redefine how clinical trials are conducted and how drugs reach the market. The integration of data and processes not only promises to improve efficiencies but could also enhance patient outcomes, ultimately transforming healthcare on a global scale.

For more detailed insights on Veeva's Development Cloud, visit veeva.com/DevelopmentCloud.

To learn about Boehringer Ingelheim's continued efforts in drug development and sustainability initiatives, check out their official website boehringer-ingelheim.com.